Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319709 | 0.81 | TET2 (0.32) | — | |
| SCHEMBL533275 | 0.81 | PRNP (0.42) | DYRK1ADYRK1BHTTLMNAPRNP | |
| SCHEMBL5232713 | 0.78 | DYRK1A (0.33) | DYRK1AHTTKMT2A | |
| SCHEMBL1928507 | 0.78 | DYRK1A (0.40) | DYRK1ADYRK1BHTTLMNAKMT2A | |
| SCHEMBL534734 | 0.78 | PLAU (0.39) | DYRK1ADYRK1BHTTLMNAPRNP | |
| SCHEMBL1927586 | 0.78 | ESR1 (0.33) | DYRK1ADYRK1BHTTLMNAPRNP | |
| SCHEMBL534655 | 0.78 | HTT (0.40) | DYRK1ADYRK1BHTTLMNAPRNP | |
| SCHEMBL3100730 | 0.74 | ESR1 (0.33) | DYRK1AHTTLMNAPRNPHPGD | |
| SCHEMBL31716251 | 0.73 | DYRK1A (0.34) | DYRK1AHTTKMT2A | |
| SCHEMBL1928088 | 0.71 | KMT2A (0.43) | HTTLMNAHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101115748-B | Acetamide compounds as fungicides | SYNGENTA PARTICIPATIONS AG | 2011-06-08 | — | — | CN | disclosed |
| US-7956188-B2 | N-substituted-2-alkylthio-2-(substituted aryloxy and heteroaryloxy)alkylamides and their sulphinyl and sulphonyl derivatives such as 2-(3,5-dichlorophenoxy)-2-methylthio-N-2-methylprop-2-yl acetamide; fungal infections of plants | SYNGENTA CROP PROTECTION, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| EP-1817309-B1 | ACETAMIDE COMPOUNDS AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20080171767-A1 | N-substituted-2-alkylthio-2-(substituted aryloxy and heteroaryloxy)alkylamides and their sulphinyl and sulphonyl derivatives such as 2-(3,5-dichlorophenoxy)-2-methylthio-N-2-methylprop-2-yl acetamide; fungal infections of plants | SYNGENTA CROP PROTECTION, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| CN-101115748-A | Acetamide compounds as fungicides | SYNGENTA PARTICIPATIONS AG (CH) | 2008-01-30 | — | — | CN | disclosed |
| EP-1817309-A1 | ACETAMIDE COMPOUNDS AS FUNGICIDES | Syngeta Participations AG (CH) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006058700-A1 | ACETAMIDE COMPOUNDS AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171767-A1 | N-substituted-2-alkylthio-2-(substituted aryloxy and heteroaryloxy)alkylamides and their sulphinyl and sulphonyl derivatives such as 2-(3,5-dichlorophenoxy)-2-methylthio-N-2-methylprop-2-yl acetamide; fungal infections of plants | NAT1, DPM1, AADAC | DYRK1A 2692/4885DYRK1B 3169/4885HTT 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.